National Mutual Insurance Federation of Agricultural Cooperatives Invests $15.06 Million in Eli Lilly and Company (NYSE:LLY)

National Mutual Insurance Federation of Agricultural Cooperatives acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 17,000 shares of the company’s stock, valued at approximately $15,061,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in LLY. Lynx Investment Advisory bought a new stake in shares of Eli Lilly and Company during the 2nd quarter worth $32,000. LGT Financial Advisors LLC purchased a new stake in Eli Lilly and Company during the second quarter valued at about $36,000. Redmont Wealth Advisors LLC bought a new stake in Eli Lilly and Company during the first quarter worth about $40,000. Morton Brown Family Wealth LLC boosted its holdings in shares of Eli Lilly and Company by 45.5% in the 2nd quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock worth $41,000 after purchasing an additional 15 shares in the last quarter. Finally, Cedar Mountain Advisors LLC increased its position in shares of Eli Lilly and Company by 53.3% during the 3rd quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company’s stock valued at $41,000 after purchasing an additional 16 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Up 0.2 %

Shares of Eli Lilly and Company stock opened at $892.70 on Monday. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a 12-month low of $547.61 and a 12-month high of $972.53. The company has a market cap of $848.43 billion, a P/E ratio of 131.47, a PEG ratio of 3.24 and a beta of 0.42. The company’s fifty day simple moving average is $919.74 and its two-hundred day simple moving average is $863.20.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The company had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. Research analysts anticipate that Eli Lilly and Company will post 14.05 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on LLY shares. Morgan Stanley reaffirmed an “overweight” rating and issued a $1,106.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Sanford C. Bernstein started coverage on shares of Eli Lilly and Company in a research note on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price objective for the company. JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. Citigroup raised their price objective on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a research note on Friday. Finally, Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,013.41.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.